Findings

What do systematic reviews say?

54 questions · 55 findings · 9 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 10 · 18.2%GRADE not reported 8 · 14.5%Very low 6 · 10.9%Low 7 · 12.7%Moderate 24 · 43.6%High 0 · 0%

Salbutamol vs placebo/no treatment

Duration of oxygen therapy (hours) · patients with the management of transient tachypnea of the newborn

1 finding from 1 review

Salbutamol for transient tachypnea of the newborn 2021 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 338 participants
Very low

Salbutamol vs placebo/no treatment

Need for continuous positive airway pressure (yes/no) · patients with the management of transient tachypnea of the newborn

It is very uncertain whether salbutamol changes need for continuous positive airway pressure (yes/no) compared with placebo/no treatment (very low certainty).

1 finding from 1 review

Salbutamol for transient tachypnea of the newborn 2021 · Cochrane Headline outcomes only
RR 0.73 [0.38, 1.39]
1 study · 46 participants
Very low

Salbutamol vs placebo/no treatment

Need for mechanical ventilation · patients with the management of transient tachypnea of the newborn

It is very uncertain whether salbutamol changes need for mechanical ventilation (yes/no) compared with placebo/no treatment (very low certainty).

1 finding from 1 review

Salbutamol for transient tachypnea of the newborn 2021 · Cochrane Headline outcomes only
RR 0.6 [0.13, 2.86]
3 studies · 254 participants
Very low

Salbutamol vs placebo/no treatment

Duration of respiratory support (intermittent positive pressure ventilation or continuous positive airway pressure; hours). · patients with the management of transient tachypnea of the newborn

1 finding from 1 review

Salbutamol for transient tachypnea of the newborn 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 228 participants
Very low

Salbutamol vs placebo/no treatment

Length of hospital stay · patients with the management of transient tachypnea of the newborn

1 finding from 1 review

Salbutamol for transient tachypnea of the newborn 2021 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 338 participants
Low

Salbutamol vs placebo/no treatment

Duration of mechanical ventilation · patients with the management of transient tachypnea of the newborn

The review found no eligible studies for this question.

1 finding from 1 review

Salbutamol for transient tachypnea of the newborn 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Salbutamol vs placebo/no treatment

Pneumothorax · patients with the management of transient tachypnea of the newborn

It is very uncertain whether salbutamol changes pneumothorax (yes/no) compared with placebo/no treatment (very low certainty).

1 finding from 1 review

Salbutamol for transient tachypnea of the newborn 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 80 participants
Very low

Magnesium sulphate or magnesium sulphate + salbutamol vs salbutamol

Time to recovery · children from 1 month to 24 months old with acute bronchiolitis

The review found no eligible studies for this question.

1 finding from 1 review

Magnesium sulphate for treating acute bronchiolitis in children up to two years of age 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Magnesium sulphate or magnesium sulphate + salbutamol vs salbutamol

All‐cause mortality · children from 1 month to 24 months old with acute bronchiolitis

1 finding from 1 review

Magnesium sulphate for treating acute bronchiolitis in children up to two years of age 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 56 participants
GRADE not reported

Magnesium sulphate or magnesium sulphate + salbutamol vs salbutamol

Adverse events · children from 1 month to 24 months old with acute bronchiolitis

1 finding from 1 review

Magnesium sulphate for treating acute bronchiolitis in children up to two years of age 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 56 participants
GRADE not reported

Magnesium sulphate or magnesium sulphate + salbutamol vs salbutamol

Length of hospital stay · children from 1 month to 24 months old with acute bronchiolitis

1 finding from 1 review

Magnesium sulphate for treating acute bronchiolitis in children up to two years of age 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 56 participants
GRADE not reported

Magnesium sulphate or magnesium sulphate + salbutamol vs salbutamol

Clinical severity score (CSS) (Wang score; range 0 to 12; higher = poorer outcome) measured at 0 to 24 hoursafter treatment · children from 1 month to 24 months old with acute bronchiolitis

The review found no eligible studies for this question.

1 finding from 1 review

Magnesium sulphate for treating acute bronchiolitis in children up to two years of age 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Magnesium sulphate or magnesium sulphate + salbutamol vs salbutamol

Clinical severity score (CSS) (Wang score; range 0 to 12; higher = poorer outcome) measured 25 to 48 hoursafter treatment · children from 1 month to 24 months old with acute bronchiolitis

The review found no eligible studies for this question.

1 finding from 1 review

Magnesium sulphate for treating acute bronchiolitis in children up to two years of age 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Magnesium sulphate or magnesium sulphate + salbutamol vs salbutamol

Hospital re‐admission within 30 days of discharge · children from 1 month to 24 months old with acute bronchiolitis

The review found no eligible studies for this question.

1 finding from 1 review

Magnesium sulphate for treating acute bronchiolitis in children up to two years of age 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

R‐salbutamol 0.5% topical cream vs placebo

Clearing or excellent improvement · people with discoid lupus erythematosus

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 37 participants
GRADE not reported

R‐salbutamol 0.5% topical cream vs placebo

At least 50% reduction in erythema · people with discoid lupus erythematosus

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 37 participants
GRADE not reported

R‐salbutamol 0.5% topical cream vs placebo

Quality of life measure · people with discoid lupus erythematosus

The review found no eligible studies for this question.

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

R‐salbutamol 0.5% topical cream vs placebo

Relapse · people with discoid lupus erythematosus

The review found no eligible studies for this question.

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

R‐salbutamol 0.5% topical cream vs placebo

Adverse events of medication, leading to discontinuation or significant morbidity · people with discoid lupus erythematosus

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 37 participants
Moderate

Salbutamol vs placebo

Mortality within the trial period · preterm infants (< 37 weeks GA) at risk of chronic lung disease

Summary of findings table ‐ Salbutamol showed no clear difference in mortality within the trial period compared with placebo (low certainty).

1 finding from 1 review

Inhaled bronchodilators for the prevention and treatment of chronic lung disease in preterm infants 2024 · Cochrane Headline outcomes only
RR 1.08 [0.5, 2.31]
1 study · 173 participants
Low